Advocacy intelligence hub — real-time data for patient organizations
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — PHASE1
Assistance Publique - Hôpitaux de Paris — PHASE3
TJ Biopharma Co., Ltd. — PHASE3
The First Affiliated Hospital of Soochow University — PHASE4
Beijing Children's Hospital — NA
Ann & Robert H Lurie Children's Hospital of Chicago — PHASE1, PHASE2
Beijing Friendship Hospital — PHASE2, PHASE3
The First Affiliated Hospital of Soochow University — PHASE2, PHASE3
Assistance Publique - Hôpitaux de Paris — PHASE1, PHASE2
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
GAMIFANT
(EMAPALUMAB-LZSG)standardSwedish Orphan Biovitrum AB (publ)
Interferon gamma Blocker [EPC]
12.1 Mechanism of Action Emapalumab-lzsg is a monoclonal antibody that binds to and neutralizes interferon gamma (IFNγ). Nonclinical data suggest that...
FDA Approves GAMIFANT
GAMIFANT (EMAPALUMAB-LZSG) received FDA approval.
A Rare Case Report of Primary Hepatic Lymphoma Complicated by Hemophagocytic Lymphohistiocytosis
Published in J Gastrointestin Liver Dis. Zhang Y et al.
Browse all Acquired hemophagocytic lymphohistiocytosis associated with malignant disease news →
Angela Smith, MD
Masonic Cancer Center, University of Minnesota
Maria Cancio, MD, M.D
Memorial Sloan Kettering Cancer Center
📍 NEW YORK, NY
Michael Jordan, MD
Children's Hospital Medical Center, Cincinnati
Xuefeng He, doctor
department of hematology, The First Affiliated Hospital of Soochow University
Claudia Spies, MD, Prof.
Charite University, Berlin, Germany
Melissa Hines
St. Jude Children's Research Hospital
View all Acquired hemophagocytic lymphohistiocytosis associated with malignant disease specialists →